OKYO Pharma
OKYO
3 hedge funds and large institutions have $62K invested in OKYO Pharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$60.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.25K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$515 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $54K | +$60.4K | +26,864 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $8K | +$8.25K | +3,667 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| – | +$515 | +229 | New |
|
OKYO Hedge Fund Activity: Q2 2022 in Review
3 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q2 2022, worth a combined $62K.
Buyers outnumbered sellers: 3 funds opened new OKYO positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $60.4K.
- 3 institutional investors held OKYO Pharma (OKYO) as of Q2 2022, up from 0 in Q1 2022.
- Funds reported $62K of OKYO Pharma stock for Q2 2022.
- 3 funds opened new OKYO Pharma positions in Q2 2022 and 0 closed out, a net change of +3 holders.
- The largest OKYO Pharma buyer in Q2 2022 was Citadel Advisors, an estimated $60.4K added.
Based on aggregated 13F filings for Q2 2022.